Nephrologist-led fluoroscopic PD catheter insertion enables safe urgent-start PD: five-year single-center experience Authors: Freda Zhi Yun Chua, Charmaine Si Min Sia, Faith Hui Wen See, Flora Htike Kyu, Mhu San Thwe, Behram Ali Khan, Christopher Cheang Han Leo, Umer Farooq Khan Published: 2026 ABSTRACT BackgroundTimely placement of a functional peritoneal dialysis (PD) catheter is critical for PD utilization, particularly for patients requiring urgent dialysis initiation. Nephrologist-led percutaneous catheter insertion has been proposed as a streamlined alternative to surgical placement, but outcome data remain limited in some settings.MethodsWe conducted a retrospective review of all fluoroscopy-guided percutaneous PD catheter insertions performed by an interventional nephrology service at a tertiary center between 2019 and 2023. Outcomes included successful PD initiation, feasibility of urgent-start PD, and early complications within 30 days, including bleeding, mechanical dysfunction, infection, dialysate leak, and visceral injury. Complication rates were contextualized against published benchmarks.ResultsA total of 253 catheter insertions were performed in 243 patients (mean age 60.9 years; 56.8% male). PD was successfully initiated in 243 (96.0%) cases. Urgent-start PD was implemented in 75 (29.6%) cases, with a median initiation time of 1 day, whereas elective PD started on day 19. Clinically significant bleeding occurred in 28 (11.1%) cases, with major bleeding requiring transfusion or intervention in eight (3%) patients, occurring more frequently among urgent-start patients. Early mechanical dysfunction occurred in 10 (4.0%) cases. No early exit-site infections, peritonitis, dialysate leaks, or visceral injuries were observed within 30 days. Notably, the cohort included six successful procedures on patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), a group traditionally considered technically challenging for PD access.ConclusionsA nephrologist-led, fluoroscopy-guided percutaneous PD catheter insertion program enabled timely PD initiation, including urgent-start PD, with high procedural success and low rates of serious early complications. These findings support the safety and effectiveness of nephrologist-performed PD catheter insertion within a structured interventional nephrology service.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-026-05107-5. Introduction Chronic kidney disease stage 5 (CKD-5) incidence is rising globally, increasing the demand for dialysis therapy. In Singapore, the incident dialysis population rose 31% from 383.9 per million in 2010 to 503 per million in 2018 [1]. Peritoneal dialysis (PD) remains underutilized compared to hemodialysis (HD) in many regions, though targeted initiatives aim to expand PD to address capacity and cost challenges [1]. PD is a well-established, home-based kidney replacement modality with clinical benefits including preservation of residual kidney function, hemodynamic stability, and patient autonomy [2]. Timely placement of a functional PD catheter avoids the need for temporary hemodialysis access and enables successful PD initiation. PD catheters can be inserted using open surgical, laparoscopic, peritoneoscopic or percutaneous approaches, with evidence demonstrating broadly comparable long-term catheter survival and complication rates across insertion techniques [3]. The choice of technique depends on local expertise, resource availability, urgency of dialysis initiation, and patient-specific factors such as anesthesia risk or need for concurrent surgical procedures [4]. In the United States, laparoscopic placement by surgeons is the most common approach, but many centers worldwide have adopted nephrologist-led percutaneous insertion as a streamlined, cost-effective alternative [5–7]. Nephrologist-performed PD catheter insertion allows integration of dialysis access into CKD care, potentially avoiding delays associated with surgical scheduling and reducing reliance on temporary vascular catheters [8]. This approach has demonstrated an increase in the prevalence of PD as a dialysis modality [9]. The percutaneous technique may also be particularly beneficial for frail or elderly patients unsuitable for general anesthesia [6]. Furthermore, urgent start PD, which grants the ability to initiate PD expediently (within 1–2 weeks of insertion) has emerged as an important strategy, given that a high proportion of patients start dialysis unplanned [10]. Urgent-start PD requires reliable catheter function soon after placement and careful protocols to mitigate complications [11]. With this evolving landscape of PD access, we present a five-year single-center experience with a nephrologist-led, fluoroscopy-guided percutaneous PD catheter insertion program. We describe the service model, including program structure, operator requirements, and protocol evolution, as well as the insertion technique, and evaluate short-term outcomes, including the feasibility of urgent-start PD and the incidence of early complications relative to published benchmarks for both surgical and minimally invasive PD catheter insertion techniques. We hypothesize that nephrologist-performed PD catheter insertion within a structured pre-procedural assessment and post-procedural monitoring framework can achieve complication rates comparable to international standards while facilitating safe urgent-start dialysis. Methods PD catheter insertion program This study was conducted at a tertiary care center that established an interventional nephrology (IN) service for PD access in 2015. Before this, PD catheter insertions were performed surgically by the urology service. The current care pathway for PD catheter placement is depicted in Fig. 1, illustrating the collaboration between primary nephrologists, the IN team, and PD unit staff. The IN team consists of three primary operators, all of whom are trained to insert PD catheters percutaneously under fluoroscopy guidance. Patients choosing PD as their dialysis modality during pre-dialysis CKD counselling are referred to a dedicated IN clinic for evaluation by an interventional nephrologist. The IN team assesses suitability for percutaneous PD catheter insertion. This includes a review of the patient’s medical history and drug chart for risk factors of bleeding, prior abdominal surgeries to evaluate risks of adhesions, recent imaging (ultrasound or computed tomography) to identify any organomegaly such as polycystic kidneys that could influence the entry site, and a physical exam for external deformities as well as exit site placement planning. If the patient is deemed unsuitable for percutaneous catheter placement, they are referred back to their primary nephrologist for alternative PD access planning, either via surgical or laparoscopic placement, or routed to HD. Patients medically cleared for percutaneous PD catheter insertion proceed on to elective scheduling within 1–2 weeks. The PD nursing team is involved preemptively to plan for elective PD initiation and training after PD catheter insertion. Urgent-start PD is defined as PD commencing within 10 days of catheter insertion (often within 1–7 days in our program), using low-volume exchanges in a supine position. The indications for urgent start PD are usually multifactorial, taking into account a combination of symptomatology, electrolyte disturbances, patient trajectory, and volume status. Low-volume exchanges for urgent start PD consist of fill volumes ranging from 500 to 1000 mL, adjusted according to body weight [11]. Study design A retrospective review of all PD catheter insertion procedures from 2019 to 2023 at our center was conducted. Clinical data were collected from a regularly updated PD registry, and all percutaneous PD catheter insertion cases were included without exclusions. Collected variables included patient demographics, clinical details such as prior dialysis exposure and relevant comorbidities, procedural details, and post-procedure outcomes including dialysis initiation timing and complications. Due to its retrospective nature with independently de-identified data, the study was granted a waiver by the local Institutional Review Board. Exclusions and exceptions Patients with a history of extensive abdominal surgery were deemed unsuitable for percutaneous PD catheter insertion. Those with limited prior gynecologic, urologic, or hepatobiliary surgery (e.g., cholecystectomy) proceeded with percutaneous insertion. Pre-procedure preparation All patients followed a standardized protocol to minimize infection and injury risk. One week before insertion, patients undergo skin and nasal decolonization for Staphylococcus aureus according to ISPD recommendations using chlorhexidine 4% solution and intranasal antimicrobial cream [12]. Bowel preparation is initiated with oral polyethylene glycol 0.5 L twice daily and oral bisacodyl 5 mg twice daily 2 days pre-procedure. On the procedure day, residual urine volume is assessed, and if significant, a urinary catheter is temporarily placed to decompress the bladder. Intravenous prophylactic antibiotics are administered, typically first-generation cephalosporin (cefazolin 1 g) for most patients, or vancomycin 1 g for those with Methicillin-resistant Staphylococcus Aureus colonization or severe penicillin allergy, in line with PD catheter infection prophylaxis guidelines [12]. For patients with elevated bleeding risk from uremic platelet dysfunction, defined as blood urea > 25 mmol/L, intravenous desmopressin 0.3 µg/kg (maximum dose 20 µg) is given 30–60 min pre-procedure. Patients are advised to fast from midnight the day of the procedure. Percutaneous catheter insertion technique Insertions are performed in an operating theater under local anesthesia with moderate sedation (typically intravenous midazolam and fentanyl) administered peri-procedurally by the procedurist, and continuous monitoring by an anesthesia-trained nurse. The patient is positioned supine. After sterile skin preparation and draping, 1% lignocaine is infiltrated at the intended entry site, usually located approximately 3 cm superolateral to the umbilicus on the left mid-abdomen. A small (~ 3 cm) transverse skin incision is made, and a 2.1 mm diameter, 13 cm spring loaded VERESS pneumoperitoneum needle (KARLSTORZ®) is introduced through the rectus muscle into the peritoneal cavity. Correct placement is confirmed by fluoroscopic visualization of the needle tip in the abdomen and smooth advancement of a stiff 0.035” guidewire under fluoroscopy. Real-time ultrasound guidance is used in cases with high-risk anatomy, such as polycystic kidney disease or obesity, to choose a safe trajectory and avoid organs and major blood vessels. The needle is then removed, and a peel-away introducer sheath is passed over the guidewire. A silicone, double-cuff swan neck coiled tip PD catheter (Medcomp®, 62.5 cm coiled-tip Tenckhoff type) is prepared by flushing with saline and loading it onto a stiff stylet. The stylet and catheter are advanced through the sheath into the peritoneal cavity, guided under fluoroscopy to ensure the catheter tip reaches the deep pelvis (Fig. 2A). Care is taken to ensure the catheter does not twist from its original configuration, and the deep cuff is deployed in the preperitoneal musculature near the rectus sheath. The peel-away sheath is split and removed, leaving the catheter in place. Immediate patency is tested by flushing 500–1000 mL of 0.9% normal saline through the catheter and attempting free drainage, which also helps detect any intraperitoneal bleeding (hemoperitoneum) or outflow obstruction. After intraperitoneal placement, a subcutaneous tunnel is created to an exit site located lateral and downward on the abdomen, usually avoiding skin folds or areas of compromised skin integrity. The superficial cuff is positioned about 2–4 cm from the exit site, per best-practice guidelines [2]. The transfer set is attached, and the catheter is secured and dressed with sterile occlusive dressing. Postoperative care and dialysis initiation In the recovery ward, PD catheter flushing is performed by a trained PD nurse using three rapid in-and-out flushes with 500 mL of 1.25% dialysate, without a prolonged dwell period, to confirm catheter patency and assess for bleeding or outflow obstruction. Patients are subsequently discharged following satisfactory assessment. Follow-up is arranged in 1 week for wound review together with low-volume flushes to maintain patency and check for bleeding. In elective-start patients, PD training is scheduled approximately 10–14 days post-insertion, allowing for tissue ingrowth into the cuff and minimizing early mechanical and leak complications [13]. Patients are advised to avoid wearing tight or restrictive garments over the PD catheter exit site and to always keep the catheter dry, including the use of waterproof dressings during showering and avoidance of catheter submersion. For urgent-start PD candidates who have emergent medical indications for dialysis initiation, such as uremia or volume overload, low-volume manual exchanges are initiated as early as 1-day post-insertion [11]. Exchanges are done with weight-based low tidal volumes, keeping the patient supine and ensuring the abdomen is drained during any upright activity, per published urgent-start protocols [10, 11]. Fill volumes are gradually escalated every 2–3 days as tolerated. Urgent start PD must be performed under direct supervision of medical staff to ensure correct technique and adherence to correct volumes and supine position. Patients who are medically stable and able to attend follow-up are managed through the PD unit on an outpatient basis, while those who are symptomatic and unable to travel to clinic frequently may be admitted to the ward to facilitate urgent start PD initiation. Any mechanical concerns identified in the immediate post-procedural period are promptly communicated to the IN team for assessment and management. Outcome measures We tracked early complications occurring within 30 days of catheter insertion (or up to 2 weeks after PD start, for those who started later). These were defined as follows: Bleeding: significant hemorrhage manifesting as either bleeding from the exit site or hemoperitoneum. Significant bleeding was defined as bleeding requiring intervention, including inpatient admission, transfusion, imaging, or re-operation. Hemoperitoneum was diagnosed by the presence of heavily blood-tinged dialysate, imaging, or surgical confirmation.Catheter Dysfunction: mechanical catheter issues within the first 2 weeks of PD that prevented adequate dialysate flow. Causes included intraluminal occlusion (fibrin or blood clot) or extraluminal causes such as catheter tip migration out of the pelvis or entrapment by omentum (Fig. 2B). In our program, inability to initiate PD due to outflow failure or sustained poor flows was considered primary dysfunction.Infection: any catheter-related infection within 2 weeks. Exit-site/tunnel infection was defined by purulent discharge, erythema, or tenderness localized to the exit or tunnel, with or without positive cultures. Peritoneal dialysis-associated peritonitis (PD peritonitis) was defined by abdominal pain with dialysate white cell count > 100/µL or positive dialysate culture [12]. Dialysate Leak: Leakage of dialysate to the exterior (around the catheter site) or into the abdominal wall within 30 days. This could present as swelling or wetness at the exit site, or edema in the genital or abdominal wall regions.Visceral Injury: perforation of intra-abdominal organs, or other severe adverse events. Bowel perforation is suspected if there is unexpected resistance during wire passage, feculent return in effluent, or if the patient developed peritonitic signs post-procedure. Bleeding: significant hemorrhage manifesting as either bleeding from the exit site or hemoperitoneum. Significant bleeding was defined as bleeding requiring intervention, including inpatient admission, transfusion, imaging, or re-operation. Hemoperitoneum was diagnosed by the presence of heavily blood-tinged dialysate, imaging, or surgical confirmation. Bleeding: significant hemorrhage manifesting as either bleeding from the exit site or hemoperitoneum. Significant bleeding was defined as bleeding requiring intervention, including inpatient admission, transfusion, imaging, or re-operation. Hemoperitoneum was diagnosed by the presence of heavily blood-tinged dialysate, imaging, or surgical confirmation. Catheter Dysfunction: mechanical catheter issues within the first 2 weeks of PD that prevented adequate dialysate flow. Causes included intraluminal occlusion (fibrin or blood clot) or extraluminal causes such as catheter tip migration out of the pelvis or entrapment by omentum (Fig. 2B). In our program, inability to initiate PD due to outflow failure or sustained poor flows was considered primary dysfunction. Catheter Dysfunction: mechanical catheter issues within the first 2 weeks of PD that prevented adequate dialysate flow. Causes included intraluminal occlusion (fibrin or blood clot) or extraluminal causes such as catheter tip migration out of the pelvis or entrapment by omentum (Fig. 2B). In our program, inability to initiate PD due to outflow failure or sustained poor flows was considered primary dysfunction. Infection: any catheter-related infection within 2 weeks. Exit-site/tunnel infection was defined by purulent discharge, erythema, or tenderness localized to the exit or tunnel, with or without positive cultures. Peritoneal dialysis-associated peritonitis (PD peritonitis) was defined by abdominal pain with dialysate white cell count > 100/µL or positive dialysate culture [12]. Infection: any catheter-related infection within 2 weeks. Exit-site/tunnel infection was defined by purulent discharge, erythema, or tenderness localized to the exit or tunnel, with or without positive cultures. Peritoneal dialysis-associated peritonitis (PD peritonitis) was defined by abdominal pain with dialysate white cell count > 100/µL or positive dialysate culture [12]. Dialysate Leak: Leakage of dialysate to the exterior (around the catheter site) or into the abdominal wall within 30 days. This could present as swelling or wetness at the exit site, or edema in the genital or abdominal wall regions. Dialysate Leak: Leakage of dialysate to the exterior (around the catheter site) or into the abdominal wall within 30 days. This could present as swelling or wetness at the exit site, or edema in the genital or abdominal wall regions. Visceral Injury: perforation of intra-abdominal organs, or other severe adverse events. Bowel perforation is suspected if there is unexpected resistance during wire passage, feculent return in effluent, or if the patient developed peritonitic signs post-procedure. Visceral Injury: perforation of intra-abdominal organs, or other severe adverse events. Bowel perforation is suspected if there is unexpected resistance during wire passage, feculent return in effluent, or if the patient developed peritonitic signs post-procedure. Comparative benchmark rates were obtained from contemporary literature, including meta-analyses and guidelines, to contextualize our outcomes. Relevant statistical tests including independent t-test, χ2 or Fisher Exact test were performed on SPSS Version 23.0 for comparing outcomes between groups, and p-value of < 0.05 was considered statistically significant. Fig. 1Referral pathway to interventional nephrology clinic for peritoneal dialysis catheter insertion. Interventional nephrologists conduct peri-procedure assessments, surgical planning, and management. The PD unit subsequently initiates dialysis. Immediate catheter-related complications or flow dysfunction are referred to the interventional nephrology team. PD = Peritoneal Dialysis. IN = Interventional Nephrology, OT = Operating Theater Referral pathway to interventional nephrology clinic for peritoneal dialysis catheter insertion. Interventional nephrologists conduct peri-procedure assessments, surgical planning, and management. The PD unit subsequently initiates dialysis. Immediate catheter-related complications or flow dysfunction are referred to the interventional nephrology team. PD = Peritoneal Dialysis. IN = Interventional Nephrology, OT = Operating Theater Fig. 2A: Shows placement of PD catheter in the lower pelvis using fluoroscopy guidance. B: shows migration of the catheter tip to the right quadrant, with extensive fecal loading in the descending colon and rectum A: Shows placement of PD catheter in the lower pelvis using fluoroscopy guidance. B: shows migration of the catheter tip to the right quadrant, with extensive fecal loading in the descending colon and rectum Results Patient characteristics Over 5 years, 253 PD catheter insertion procedures were performed in 243 unique patients. Catheter adjustments, exit site adjustments, and removals were excluded. Baseline characteristics are summarized in Table 1. The mean patient age was approximately 61 years, and 57% were male. The majority, 198 (78.3%) of procedures were for dialysis initiation in CKD-5 patients, 48 (18.9%) were for conversion from chronic HD to PD, and six (2.4%) were for catheter replacement due to infection or malfunction in prevalent PD patients. The leading cause of CKD was diabetes. The annual numbers of catheters placed, including the number of urgent and elective-starts per year are shown in Fig. 3. Dialysis initiation and success of procedure Following catheter placement, 244 of the 253 procedures (96.4%) successfully led to PD initiation, while nine did not. The reasons included: persistent exit-site bleeding leading to catheter removal before use (one procedure); primary mechanical failure, such as immediate migration or outflow failure (three procedures); and late tunnel tract infections requiring removal (two procedures). In one complex case, a patient with severe PD peritonitis had refractory membrane failure upon PD re-initiation and ultimately could not continue PD despite two catheter revisions (two procedures). There was also one pre-urgent-start PD initiation mortality secondary to massive hemoperitoneum post-procedure, who succumbed despite surgical intervention (one procedure). The median time to dialysis initiation for elective-start PD was 19 days (Table 1). Urgent start PD Urgent-start PD was implemented in 75 cases (29.6%) within 10 days of catheter insertion, with a median time to initiation of 1 day (Table 1). Figure 3 demonstrates the rates of urgent start PD per year, and Table 2 compares clinical parameters and complication rates between urgent and elective PD initiation. Patients requiring urgent start PD had higher urea (29.1 vs. 25 mmol/L, p = 0.003) and creatinine (781.2 vs. 650.9 µmol/L, p < 0.001), and lower hemoglobin (9.1 vs. 10.1 g/dL, p < 0.001) than those starting PD electively. Urgent-start PD patients experienced higher rates of significant bleeding, including exit-site bleeding and hemoperitoneum, compared with non-urgent-start patients (20% vs. 6.5%, p = 0.003), with some cases requiring hospital admission, blood transfusion, and imaging. Patients with autosomal dominant polycystic kidney disease (ADPKD) Six PD catheter insertion procedures were performed in five unique ADPKD patients. All six procedures had immediate catheter patency and no peri-procedure complications, while five of six procedures (83%) had sustained technique survival greater than 1 year. One patient required catheter removal and successful re-insertion using percutaneous technique after 11 months due to recurrent peritonitis. Complications Bleeding Clinically significant bleeding was noted in 28 cases (11.1% of insertions), and 24 cases (9.5% of insertions) were exit-site bleeding (Table 2). In 81% of the bleeding cases, the onset was within 3 days of insertion. Ten patients with mild exit bleeding were managed with outpatient pressure dressings and did not require admission. Fifteen patients had more prolonged or recurrent bleeding requiring hospital observation; of these, eight patients received blood transfusions due to significant hemoglobin drop or symptomatic anemia. Only two cases qualified as massive hemoperitoneum: one patient developed tense distension with intraperitoneal blood and hypotension, necessitating urgent laparotomy. The second hemoperitoneum case was less severe and was managed non-operatively with transfusion, regular intraperitoneal heparin, and urgent-start PD. No cases of organ laceration were identified as bleeding sources. Seven patients had PD catheter insertion done while on dual antiplatelet therapy (DAPT). One patient required urgent start PD. Two patients had exit site bleeding, of which one required hospital admission, while other was managed in the ambulatory setting. None of the patients required transfusions. Mean hemoglobin among patients on DAPT was 10.5 g/dL (7.9–11.7 g/dL). Mechanical catheter dysfunction Early mechanical problems occurred in 10 cases (4.0%). Of these, catheter tip migration out of the pelvis was the most frequent cause (six cases). Tip migration typically presented as outflow failure soon after starting PD. In four of the six cases, the catheter was repositioned: two were successfully exchanged percutaneously with a guidewire under fluoroscopy, and two required laparoscopic adjustment with omentopexy. The remaining two patients opted to switch to HD. One patient had a tight superficial tunnel causing kinking of the catheter, which was corrected by revising the tunnel under local anesthesia. Infections No PD-related exit site infections or peritonitis were recorded in the first 30 post-operative days. Notably, two patients developed late exit site infection (6–8 weeks post-insertion) after they had initiated home PD. Both patients responded initially to antibiotics, but one required catheter removal at 3 months for persistent infection. Dialysate leak and visceral injury None of the patients experienced dialysate leakage from the wound or tracking of fluid into the subcutaneous tissues within the first month. There were no bladder or bowel perforations. Table 1Baseline characteristics of individual patients (N = 243)Patient DemographicsVariableFreq (Percentage)Age at time of procedure (Mean, Range)60.9 (22–94)Sex Male138 (56.8%) Female105 (43.2%)Ethnicity Chinese168 (69.1%) Malay32 (13.2%) Indian22 (9.1%)CKD Etiology Diabetes Mellitus Hypertension Biopsy-proven glomerulonephritis ADPKD Others143 (58.8%)57 (23.5%)29 (11.9%)5 (2.1%)9 (3.7%)Prior dialysis modality before PD catheter insertion (N = 253 procedures) CKD5198 (78.3%) HD48 (18.9%) PD◊6 (2.4%) Renal transplant1 (0.4%)Dual Antiplatelet therapy at time of evaluation9 (3.7%) Continued dual antiplatelets7 (2.9%)PD start type Elective169 (66.8%) Urgent start75 (30.9%) Not started9 (3.6%)Median days from catheter insertion to PD initiation All patients12 (0–173) Elective initiation19 (12–173) Urgent start1 (1–10) Laboratory values ( N = 253 procedures) Mean (Range) Hemoglobin (g/dL)9.9 (6.6–12.2)Urea (mmol/L)26.3 (4.0–46.9)Creatinine (µmol/L)689.0 (159–1529)◊ This represents prevalent PD patients who required a repeat PD catheter insertion Table 1Baseline characteristics of individual patients (N = 243)Patient DemographicsVariableFreq (Percentage)Age at time of procedure (Mean, Range)60.9 (22–94)Sex Male138 (56.8%) Female105 (43.2%)Ethnicity Chinese168 (69.1%) Malay32 (13.2%) Indian22 (9.1%)CKD Etiology Diabetes Mellitus Hypertension Biopsy-proven glomerulonephritis ADPKD Others143 (58.8%)57 (23.5%)29 (11.9%)5 (2.1%)9 (3.7%)Prior dialysis modality before PD catheter insertion (N = 253 procedures) CKD5198 (78.3%) HD48 (18.9%) PD◊6 (2.4%) Renal transplant1 (0.4%)Dual Antiplatelet therapy at time of evaluation9 (3.7%) Continued dual antiplatelets7 (2.9%)PD start type Elective169 (66.8%) Urgent start75 (30.9%) Not started9 (3.6%)Median days from catheter insertion to PD initiation All patients12 (0–173) Elective initiation19 (12–173) Urgent start1 (1–10) Laboratory values ( N = 253 procedures) Mean (Range) Hemoglobin (g/dL)9.9 (6.6–12.2)Urea (mmol/L)26.3 (4.0–46.9)Creatinine (µmol/L)689.0 (159–1529)◊ This represents prevalent PD patients who required a repeat PD catheter insertion Baseline characteristics of individual patients (N = 243) Diabetes Mellitus Hypertension Biopsy-proven glomerulonephritis ADPKD Others 143 (58.8%) 57 (23.5%) 29 (11.9%) 5 (2.1%) 9 (3.7%) ◊ This represents prevalent PD patients who required a repeat PD catheter insertion Table 2Incidence of procedure-related complications in elective and urgent PD start patientsTotalN = 253+Elective StartN = 169 (69.3%)Urgent StartN = 75 (29.6%)p-valueClinical Characteristics(Mean, SD)Age60.9 (014.1)61.5 (013.8)59.9 (014.4)0.384Urea (mmol/L)26.3 (008.8)25.0 (007.5)29.1 (010.8) 0.003 * Creatinine (µmol/L)689.0 (215.8)650.9 (168.4)781.2 (278.6) < 0.001 * Hemoglobin (g/dL)9.9 (001.7)10.1 (001.8)9.1 (001.2) < 0.001 * Complications N, (%)Bleeding28 (11.1%)11 (6.5%)15 (20.0%) 0.003 ± Exit Site Bleeding24 (9.5%)11 (6.5%)12 (16.0%) 0.016 ± Hemoperitoneum◊4 (1.6%)0 (0.0%)3 (4.0%) 0.013 ° Requiring Transfusion8 (3.2%)0 (0.0%)6 (8.0%) 0.003 ° Requiring Admission16 (6.4%)3 (1.8%)11 (14.7%) 0.004 ° Requiring CT scan3 (1.2%)0 (0.0%)3 (4.0%) 0.013 ° Primary Mechanical Issue10 (4.0%)3 (1.8%)3 (04.0%)0.375± Catheter migration6 (2.4%)3 (1.8%)2 (02.7%)0.650°Infectious complications000N/A Exit site infection000N/A PD peritonitis000N/ALeaks000N/AOrgan perforation000N/AMortality101N/A+9 patients not initiated on PD. *Adjusted for unequal variances. on D ±χ2 test. °Fisher Exact Test. CT = computed tomography. ◊ There was 1 patient mortality amongst the urgent start cases Table 2Incidence of procedure-related complications in elective and urgent PD start patientsTotalN = 253+Elective StartN = 169 (69.3%)Urgent StartN = 75 (29.6%)p-valueClinical Characteristics(Mean, SD)Age60.9 (014.1)61.5 (013.8)59.9 (014.4)0.384Urea (mmol/L)26.3 (008.8)25.0 (007.5)29.1 (010.8) 0.003 * Creatinine (µmol/L)689.0 (215.8)650.9 (168.4)781.2 (278.6) < 0.001 * Hemoglobin (g/dL)9.9 (001.7)10.1 (001.8)9.1 (001.2) < 0.001 * Complications N, (%)Bleeding28 (11.1%)11 (6.5%)15 (20.0%) 0.003 ± Exit Site Bleeding24 (9.5%)11 (6.5%)12 (16.0%) 0.016 ± Hemoperitoneum◊4 (1.6%)0 (0.0%)3 (4.0%) 0.013 ° Requiring Transfusion8 (3.2%)0 (0.0%)6 (8.0%) 0.003 ° Requiring Admission16 (6.4%)3 (1.8%)11 (14.7%) 0.004 ° Requiring CT scan3 (1.2%)0 (0.0%)3 (4.0%) 0.013 ° Primary Mechanical Issue10 (4.0%)3 (1.8%)3 (04.0%)0.375± Catheter migration6 (2.4%)3 (1.8%)2 (02.7%)0.650°Infectious complications000N/A Exit site infection000N/A PD peritonitis000N/ALeaks000N/AOrgan perforation000N/AMortality101N/A+9 patients not initiated on PD. *Adjusted for unequal variances. on D ±χ2 test. °Fisher Exact Test. CT = computed tomography. ◊ There was 1 patient mortality amongst the urgent start cases Incidence of procedure-related complications in elective and urgent PD start patients Clinical Characteristics (Mean, SD) +9 patients not initiated on PD. *Adjusted for unequal variances. on D ±χ2 test. °Fisher Exact Test. CT = computed tomography. ◊ There was 1 patient mortality amongst the urgent start cases Fig. 3Annual number of percutaneous PD catheters inserted under the nephrologist-led IN program Annual number of percutaneous PD catheters inserted under the nephrologist-led IN program Discussion Nephrologist-led PD access and urgent start PD In this 5-year single-center experience, a nephrologist-led, fluoroscopy-guided percutaneous PD catheter insertion program achieved high procedural success and facilitated timely dialysis initiation, including urgent-start PD, with low rates of serious early complications. These findings are consistent with prior observational studies demonstrating that nephrologist-led fluoroscopy-guided percutaneous PD catheter insertion yields infection rates, mechanical complications, and catheter survival comparable to those reported with surgical insertion techniques [14]. Nearly all insertions led to successful PD initiation, and urgent-start PD was feasible in approximately one-third of cases. The consistent annual catheter volumes and urgent start PD rate suggest that this model facilitates timely PD initiation, supporting the safety of nephrologist-performed percutaneous insertion when delivered within a structured program. Urgent-start PD is a viable alternative to unplanned HD via central venous catheters, and prior studies support the feasibility of using low-volume, supine exchanges with close monitoring [11]. In our cohort, urgent-start PD was started within 10 days of insertion, most within 24 to 48 h, with no early dialysate leaks or infectious complications, consistent with reports that early PD initiation does not inherently increase peritonitis or leak risk when protocols are followed [15]. However, urgent-start patients had more severe uremia and anemia and experienced higher bleeding-related complications, indicating that urgent-start PD, while feasible, is not risk-neutral. Although we did not evaluate health economic outcomes, prior work suggested urgent-start PD programs can reduce hospitalization duration and hemodialysis catheter-related complications [16]. Complications Bleeding was the most frequent early complication, although most events were minor exit-site bleeding, which is inconsistently reported in literature. Clinically significant bleeding requiring transfusion or intervention was approximately 3%, within the range reported for both surgical and percutaneous series [17]. Urgent-start patients accounted for a disproportionate share of bleeding events in our cohort, consistent with reports linking urgent initiation with increased bleeding events [3]. While there is no consensus on a threshold for severe uremia, our results demonstrate an association between severe uraemia and bleeding risk in this patient population. Given the high baseline bleeding risk in advanced kidney disease due to uremic platelet dysfunction, shared decision-making and individualized peri-procedural management of antiplatelet and anticoagulant therapy are essential, weighing risks and benefits of thrombotic events [3, 18]. Similarly, data on peri-procedure antiplatelet use is limited in this cohort. Antiplatelets were generally continued for patients in our study due to their cardiovascular risk profile, and seven patients were continued on dual antiplatelets, showing comparable bleeding risk to reported literature. Conservative management of exit-site bleeding includes local compression with circumferential pressure dressing and temporary immobilization. Supportive measures may include urgent-start PD to reduce uremia, intravenous desmopressin (0.3 mcg/kg), and transfusion where indicated. Notably, evidence supporting prophylactic desmopressin use for PD catheter insertion remains limited, with most data extrapolated from native kidney biopsy studies demonstrating reduced bleeding complications across various CKD stages [19, 20]. Subcutaneous epinephrine (1 mg diluted in 10 mL normal saline) around the external cuff and tunnel tract can aid hemostasis [21]. The catheter should be flushed to assess for hemoperitoneum, which, if present, should prompt repeated flushes to assess for persistence and to maintain catheter patency. Finally, intraperitoneal heparin 500 units/L can be instilled to reduce intraluminal clot formation. Systemic absorption at this dose is minimal, and prior studies have demonstrated reduced intraperitoneal fibrin formation without the risk of systemic anticoagulation [22, 23]. Early mechanical dysfunction occurred in 4% of procedures, predominantly due to catheter tip migration. This compares favorably with published ranges of 5 to 15% for surgical and percutaneous techniques, depending on definitions and follow-up duration [24, 25]. A meta-analysis comparing percutaneous and surgical insertion reported similar dysfunction rates (16.7% vs. 16.8%) [26]. Our cohort’s early mechanical complication rates also fall within the ISPD guideline’s recommended patency rate of 80% at 1 year [24, 26]. Mechanical issues range 0.9–4.2% using percutaneous PD catheter insertion technique [14, 27], and are mitigated by emphasizing bowel preparation, confirming catheter position under fluoroscopy, and adjusting the catheter in real time to position it in the pelvis [28]. A stylet was used for pelvic placement and advanced under fluoroscopy to reduce injury risk. Techniques not employing direct visualization with fluoroscopy may have higher risks of catheter dysfunction (9.9%) or bowel puncture (2.5%) compared to those observed in our cohort [27]. Our protocol of intra-operative flushing, post-operative flushing in recovery ward by the PD nurse, and early post-operative review in 1 week identifies mechanical issues early, which can be evaluated promptly with abdominal radiography to assess fecal loading and catheter tip position, followed by aggressive bowel clearance, and repeat percutaneous catheter exchange where appropriate [29]. Constipation is a well-recognized and common contributor to PD catheter dysfunction through mechanical obstruction, catheter migration, and increased intra-abdominal pressure; accordingly, emphasis on bowel clearance is important to reduce the risk of catheter malfunction as shown in previous randomized controlled trials. The described stepwise approach preserves surgical revision for refractory dysfunction requiring adjunctive procedures such as omentopexy. Our cohort had no early exit-site infections, tunnel infections, or peritonitis within 30 days. This exceeds commonly cited early infection rates of approximately 1 to 5% reported in literature [12, 24]. Individual retrospective analyses of percutaneous catheter insertions by nephrologists and meta-analyses report a lower infection risk with the percutaneous technique compared to surgical insertion [14, 27, 30]. Standardized decolonization, antibiotic prophylaxis, strict aseptic technique in the operating theatre, and structured PD nursing education for early wound care likely contributed to these outcomes. During the first two weeks, the PD catheter is handled solely by PD nursing and trained PD or interventional nephrologists, thereby further reducing the chance of contamination. No bowel or bladder perforations occurred. Emphasis on pre-operative bowel clearance, using the Seldinger technique under fluoroscopic guidance, adjunct ultrasound for high-risk anatomy such as polycystic kidney disease, and routine bladder decompression likely reduced visceral injury risk, consistent with prior reports [17]. ISPD guidelines recommend reporting peri-catheter leak rates within 30 days separately from later leaks, as the latter may not be due to surgical etiology. Reported leak rates related to procedures are variable and can be as high as 12.8% [17]. Percutaneous insertion may have a lower leak risk than surgical insertion, with a reported 0.35 risk reduction ratio [31]. The absence of early leaks in our study despite frequent urgent-start PD likely reflects careful site selection and strict adherence to supine, low-volume urgent-start PD protocols. Overall, early infection and leak rates were lower than typically reported, mechanical dysfunction rates were at the lower end of published ranges, and major bleeding rates were comparable to those described for both surgical and percutaneous cohorts. ISPD guidelines recommend an annual audit, targeting catheter patency rates greater than 80% at 12 months, infection rates less than 5%, and visceral injury and significant hemorrhage rates less than 1% [24]. Patients with autosomal dominant polycystic kidney disease PD catheter insertion in patients with ADPKD is technically challenging with elevated risks due to enlarged kidneys, reduced intraperitoneal space, and altered intra-abdominal anatomy, raising concerns regarding mechanical complications and long-term technique survival. Hence, there is limited data describing technique safety in this population. In our series, physician-led fluoroscopically guided PD catheter insertion was feasible and associated with favorable catheter outcomes in this subgroup. All patients achieved functional peritoneal dialysis access, with sustained technique survival. Despite the small numbers, our experience suggests that ADPKD should not be considered a prohibitive barrier to percutaneous nephrologist-performed PD catheter insertion and support the utility of this approach even in anatomically complex patients. PD catheter insertion protocol evolutions Over 5 years, we refined protocols based on annual audits. Recognizing the association between urgent-start PD and bleeding, we increased cessation of antiplatelets where feasible, used ultrasound to identify major vessels before puncture, considered peri-procedure subcutaneous diluted epinephrine injections, and intensified early post-procedure monitoring for higher-risk patients. We have also utilized intraperitoneal contrast in selected cases to further confirm catheter placement to mitigate the risk of early PD catheter dysfunction. The program also supports nephrology trainees’ participation in catheter insertion and early complication management, building local capability. This model may be replicated through structured proctorship with surgical and nursing support, a comprehensive data collection and multidisciplinary audit system, and wider adoption could increase PD access and reduce reliance on tunneled HD catheters. Future work should evaluate longer-term catheter outcomes and PD retention associated with nephrologist-led programs. Prospective multicenter studies could improve generalizability and clarify which patients benefit most from percutaneous versus surgical approaches. Health economic analyses, including avoided temporary HD catheters and hospitalization costs, would further inform service planning. Limitations This study is limited by its retrospective, single-center design, and the absence of a contemporaneous surgical control group. Selection bias is highly likely, as patients with extensive prior abdominal surgery or complex anatomy were preferentially referred for surgical placement. Temporal bias is also present as the program has continued to evolve over time. Outcomes were focused on early complications; longer-term catheter survival and late infections were not assessed. Procedural outcomes may be influenced by operator experience and institutional case volume, which may limit the generalizability of these findings to smaller centers. Benchmarking across studies is also limited by differences in techniques, definitions of complications, and reporting standards. Conclusion A nephrologist-led, fluoroscopy-guided percutaneous PD catheter insertion program enabled timely PD initiation, including urgent-start PD, with a low incidence of serious early infective and mechanical complications. This study also demonstrated the feasibility of PD catheter insertion in a small subset of ADPKD patients and those receiving DAPT. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1